Market Cap$43.93B
P/E32.30x
PEG Ratio0.95
Div yield—
Beta1.18
IQV Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)42.37%
Price vs S&P 500 (4W)0.22%
PEG Ratio0.95
VGM Score57.58
P/E Ratio (Annual)32.30x
IQV Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $3.03 | $3.15 | +3.94%(+$0.12) | |
| Q1 2026 | $2.82 | $2.90 | +2.96%(+$0.08) | |
| Q4 2025 | $3.40 | $3.42 | +0.69%(+$0.02) | |
| Q3 2025 | $2.98 | $3.00 | +0.81%(+$0.02) | |
| Q2 2025 | $2.77 | $2.81 | +1.43%(+$0.04) |
IQV Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.03
4.07
4.14
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
| ONMDOneMedNet Corp Class A Common Stock | D | A | D | — | -6.8% | — | — | $4.51 |
About IQVIA Holdings Inc.
IQVIA provides outsourced clinical trial services and healthcare data analytics to the global pharmaceutical and healthcare industries. The company operates through two segments: Research & Development, offering late-stage clinical trials to pharmaceutical, medical device, and diagnostic companies; and Technology & Analytics, delivering aggregated data and analytics solutions to pharmaceutical firms, healthcare providers, payers, and policymakers.